PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Biological: PF-04360365 0.5 mg/kg
Biological: PF-04360365 1 mg/kg
Drug: Placebo
Biological: PF-04360365 3 mg/kg
Biological: PF-04360365 8.5 mg/kg
Biological: PF-04360365 0.1 mg/kg

First Posted Date: 2008-07-25

Last Posted Date: 2022-11-07

Lead Sponsor: Pfizer

Target Recruit Count: 198

Registration Number: NCT00722046

Locations: 🇬🇧
The Shalbourne Suite, Swindon, Wiltshire, United Kingdom
🇬🇧
Kingshill Research Centre, Swindon, Wiltshire, United Kingdom
🇺🇸
Dedicated Phase 1, Phoenix, Arizona, United States

and more 38 locations

A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers

Phase 1

Completed

Conditions: Insomnia

Interventions: Drug: PD 0200390

First Posted Date: 2008-07-25

Last Posted Date: 2011-02-04

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT00722306

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections

Completed

Conditions: Systemic Fungal Infections

Interventions: Drug: voriconazole

First Posted Date: 2008-07-24

Last Posted Date: 2011-01-10

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT00721578

Locations: 🇮🇳
Pfizer Investigational Site, New Delhi, India

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: letrozole
Drug: PD 0332991

First Posted Date: 2008-07-24

Last Posted Date: 2019-11-04

Lead Sponsor: Pfizer

Target Recruit Count: 177

Registration Number: NCT00721409

Locations: 🇺🇸
Central Hematology Oncology Medical group Inc., Alhambra, California, United States
🇺🇸
TORI -US Central Administration (Regulatory Management), Los Angeles, California, United States
🇺🇸
TORI -US Central Administration, Los Angeles, California, United States

and more 87 locations

A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.

Phase 1

Terminated

Conditions: Renal Insufficiency
Pharmacokinetics

Interventions: Drug: PD 0332334

First Posted Date: 2008-07-24

Last Posted Date: 2010-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT00721422

Locations: 🇺🇸
Pfizer Investigational Site, Miami, Florida, United States

A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: PF-00868554
Drug: Placebo

First Posted Date: 2008-07-22

Last Posted Date: 2013-08-26

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT00720434

Locations: 🇵🇷
Pfizer Investigational Site, Santurce, Puerto Rico

Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use

Phase 4

Completed

Conditions: Tobacco Use Cessation

Interventions: Drug: Placebo
Drug: Varenicline Tartrate

First Posted Date: 2008-07-16

Last Posted Date: 2015-07-23

Lead Sponsor: Pfizer

Target Recruit Count: 432

Registration Number: NCT00717093

Locations: 🇸🇪
Pfizer Investigational Site, Umea, Sweden

Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: SUNITINIB MALATE

First Posted Date: 2008-07-16

Last Posted Date: 2023-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 472

Registration Number: NCT00716820

Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers

Phase 1

Completed

Conditions: Methodology Study

Interventions: Drug: zolpidem
Drug: placebo

First Posted Date: 2008-07-16

Last Posted Date: 2009-04-24

Lead Sponsor: Pfizer

Target Recruit Count: 11

Registration Number: NCT00716521

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: sunitinib malate

First Posted Date: 2008-07-16

Last Posted Date: 2023-05-03

Lead Sponsor: Pfizer

Target Recruit Count: 1674

Registration Number: NCT00716625

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy